The University of Chicago Header Logo

Connection

Ralph Weichselbaum to Neoplasms

Back to Details
This is a "connection" page, showing publications Ralph Weichselbaum has written about Neoplasms.
Ralph Weichselbaum
Connection Strength
12.622
Neoplasms
  1. Amphiregulin as a Mediator of Radiation-Induced Systemic Effects in Metastatic Cancer: Balancing Local Control with Distant Progression. Clin Cancer Res. 2025 Dec 01; 31(23):4899-4902.
    View in: PubMed
    Score: 0.306
  2. The dark side of radiotherapy. Cancer Cell. 2025 Aug 11; 43(8):1385-1389.
    View in: PubMed
    Score: 0.297
  3. Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
    View in: PubMed
    Score: 0.297
  4. YTHDFs as radiotherapy checkpoints in tumor immunity. J Exp Med. 2025 Aug 04; 222(8).
    View in: PubMed
    Score: 0.295
  5. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 08; 25(8):e352-e362.
    View in: PubMed
    Score: 0.279
  6. Radiotherapy and immunology. J Exp Med. 2024 07 01; 221(7).
    View in: PubMed
    Score: 0.275
  7. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.267
  8. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 12 08; 4(12):863-874.
    View in: PubMed
    Score: 0.266
  9. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.257
  10. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol. 2022 12; 17(12):1322-1331.
    View in: PubMed
    Score: 0.247
  11. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.242
  12. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
    View in: PubMed
    Score: 0.236
  13. Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy. JAMA Oncol. 2022 03 01; 8(3):333-334.
    View in: PubMed
    Score: 0.236
  14. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
    View in: PubMed
    Score: 0.230
  15. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
    View in: PubMed
    Score: 0.229
  16. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
    View in: PubMed
    Score: 0.228
  17. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179.
    View in: PubMed
    Score: 0.225
  18. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.220
  19. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
    View in: PubMed
    Score: 0.218
  20. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
    View in: PubMed
    Score: 0.205
  21. Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". Clin Cancer Res. 2020 06 15; 26(12):2777-2782.
    View in: PubMed
    Score: 0.204
  22. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
    View in: PubMed
    Score: 0.198
  23. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
    View in: PubMed
    Score: 0.193
  24. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017 Jun; 14(6):365-379.
    View in: PubMed
    Score: 0.165
  25. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.145
  26. The immunology of ablative radiation. Semin Radiat Oncol. 2015 Jan; 25(1):40-5.
    View in: PubMed
    Score: 0.143
  27. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52.
    View in: PubMed
    Score: 0.142
  28. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014 09; 11(9):549-57.
    View in: PubMed
    Score: 0.138
  29. Radiation as an immune modulator. Semin Radiat Oncol. 2013 Oct; 23(4):273-80.
    View in: PubMed
    Score: 0.132
  30. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.123
  31. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012 Jun 01; 18(11):3015-21.
    View in: PubMed
    Score: 0.120
  32. A downside to apoptosis in cancer therapy? Nat Med. 2011 Jul 07; 17(7):780-2.
    View in: PubMed
    Score: 0.113
  33. Oligometastases revisited. Nat Rev Clin Oncol. 2011 06; 8(6):378-82.
    View in: PubMed
    Score: 0.110
  34. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010 Feb 15; 70(4):1534-43.
    View in: PubMed
    Score: 0.102
  35. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009 Aug; 16(8):609-19.
    View in: PubMed
    Score: 0.097
  36. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.092
  37. Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB. Int J Oncol. 2007 Dec; 31(6):1519-28.
    View in: PubMed
    Score: 0.088
  38. Characterization of the theorectical radiation dose enhancement from nanoparticles. Technol Cancer Res Treat. 2007 Oct; 6(5):395-401.
    View in: PubMed
    Score: 0.087
  39. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol. 2007 Oct; 3(5):545-56.
    View in: PubMed
    Score: 0.087
  40. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46.
    View in: PubMed
    Score: 0.081
  41. Radiation Oncology-Biology Integration Network: Bridging the Gap between Biological Research and Clinical Practice. Clin Cancer Res. 2026 Jun 15; 32(12):2340-2351.
    View in: PubMed
    Score: 0.079
  42. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006 Jan 01; 13(1):1-6.
    View in: PubMed
    Score: 0.077
  43. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 01 05; 223(1).
    View in: PubMed
    Score: 0.076
  44. Chemo-inducible gene therapy. Anticancer Drugs. 2005 Nov; 16(10):1053-8.
    View in: PubMed
    Score: 0.076
  45. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res. 2005 Oct 15; 65(20):9479-84.
    View in: PubMed
    Score: 0.076
  46. A universal chimeric antigen receptor (CAR)-fragment antibody binder (FAB) split system for cancer immunotherapy. Sci Adv. 2025 Jul 04; 11(27):eadv4937.
    View in: PubMed
    Score: 0.074
  47. Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade. Nat Genet. 2025 Aug; 57(8):1802-1811.
    View in: PubMed
    Score: 0.074
  48. Radiation's outer limits. Nat Med. 2005 May; 11(5):477-8.
    View in: PubMed
    Score: 0.073
  49. Transforming malignant tumors into vulnerable phenotypes via nanoscale coordination polymer mediated cell senescence and photodynamic therapy. Biomaterials. 2025 Nov; 322:123355.
    View in: PubMed
    Score: 0.073
  50. Designing live bacterial therapeutics for cancer. Adv Drug Deliv Rev. 2025 06; 221:115579.
    View in: PubMed
    Score: 0.073
  51. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol. 2025 Mar; 26(3):e152-e170.
    View in: PubMed
    Score: 0.073
  52. N6-methyladenosine reader YTHDF2 in cell state transition and antitumor immunity. RNA. 2025 02 19; 31(3):395-401.
    View in: PubMed
    Score: 0.072
  53. Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. Oncoimmunology. 2025 Dec; 14(1):2432726.
    View in: PubMed
    Score: 0.072
  54. Bifunctional Metal-Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio-Immunotherapy. Angew Chem Int Ed Engl. 2025 Jan 27; 64(5):e202417027.
    View in: PubMed
    Score: 0.071
  55. Multifunctional Nanomaterials Mediate Cholesterol Depletion for Cancer Treatment. Angew Chem Int Ed Engl. 2024 11 11; 63(46):e202412844.
    View in: PubMed
    Score: 0.071
  56. Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. Clin Cancer Res. 2024 Oct 01; 30(19):4450-4463.
    View in: PubMed
    Score: 0.070
  57. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
    View in: PubMed
    Score: 0.070
  58. Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst). 2004 Aug-Sep; 3(8-9):1245-51.
    View in: PubMed
    Score: 0.070
  59. Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 10 10; 42(29):3387-3391.
    View in: PubMed
    Score: 0.070
  60. Immunogenic Bifunctional Nanoparticle Suppresses Programmed Cell Death-Ligand 1 in Cancer and Dendritic Cells to Enhance Adaptive Immunity and Chemo-Immunotherapy. ACS Nano. 2024 02 13; 18(6):5152-5166.
    View in: PubMed
    Score: 0.067
  61. Nanoscale Covalent Organic Framework with Staggered Stacking of Phthalocyanines for Mitochondria-Targeted Photodynamic Therapy. J Am Chem Soc. 2024 01 10; 146(1):849-857.
    View in: PubMed
    Score: 0.067
  62. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004 Jan 16; 279(3):2273-80.
    View in: PubMed
    Score: 0.066
  63. Mechanoregulatory Cholesterol Oxidase-Functionalized Nanoscale Metal-Organic Framework Stimulates Pyroptosis and Reinvigorates T Cells. Small. 2023 12; 19(52):e2305440.
    View in: PubMed
    Score: 0.065
  64. Nanoscale Metal-Organic Framework with an X-ray Triggerable Prodrug for Synergistic Radiotherapy and Chemotherapy. J Am Chem Soc. 2023 08 30; 145(34):18698-18704.
    View in: PubMed
    Score: 0.065
  65. Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
    View in: PubMed
    Score: 0.065
  66. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther. 2003 Jul-Aug; 2(4):326-9.
    View in: PubMed
    Score: 0.065
  67. YTHDF2/m6 A/NF-?B axis controls anti-tumor immunity by regulating intratumoral Tregs. EMBO J. 2023 08 01; 42(15):e113126.
    View in: PubMed
    Score: 0.064
  68. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
    View in: PubMed
    Score: 0.064
  69. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
    View in: PubMed
    Score: 0.064
  70. Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy. Adv Mater. 2023 May; 35(21):e2206370.
    View in: PubMed
    Score: 0.064
  71. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785.
    View in: PubMed
    Score: 0.062
  72. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
    View in: PubMed
    Score: 0.062
  73. TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer. Biomaterials. 2022 11; 290:121831.
    View in: PubMed
    Score: 0.061
  74. Metastasis. Cancer Cell. 2022 08 08; 40(8):787-791.
    View in: PubMed
    Score: 0.061
  75. Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. Nat Biomed Eng. 2022 02; 6(2):144-156.
    View in: PubMed
    Score: 0.059
  76. Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. Int J Oncol. 2001 Oct; 19(4):833-5.
    View in: PubMed
    Score: 0.057
  77. Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
    View in: PubMed
    Score: 0.057
  78. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.056
  79. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 06 15; 6(60).
    View in: PubMed
    Score: 0.056
  80. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci Immunol. 2021 05 07; 6(59).
    View in: PubMed
    Score: 0.056
  81. Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
    View in: PubMed
    Score: 0.054
  82. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 2000 Dec 15; 60(24):6958-63.
    View in: PubMed
    Score: 0.054
  83. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.053
  84. Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. Sci Adv. 2020 10; 6(40).
    View in: PubMed
    Score: 0.053
  85. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.053
  86. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000 Sep-Oct; 6(5):287-93.
    View in: PubMed
    Score: 0.053
  87. Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clin Cancer Res. 2020 09 15; 26(18):4723-4736.
    View in: PubMed
    Score: 0.052
  88. Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities. Cancer J. 2019 Mar/Apr; 25(2):106-115.
    View in: PubMed
    Score: 0.048
  89. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019 02; 566(7743):270-274.
    View in: PubMed
    Score: 0.048
  90. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
    View in: PubMed
    Score: 0.047
  91. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.045
  92. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.045
  93. Role of gene therapy in radiation oncology. Cancer Treat Res. 1998; 93:153-67.
    View in: PubMed
    Score: 0.044
  94. Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
    View in: PubMed
    Score: 0.044
  95. Gene therapy of cancer. Lancet. 1997 May; 349 Suppl 2:SII10-2.
    View in: PubMed
    Score: 0.042
  96. Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature. 2017 05 04; 545(7652):98-102.
    View in: PubMed
    Score: 0.042
  97. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
    View in: PubMed
    Score: 0.041
  98. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
    View in: PubMed
    Score: 0.041
  99. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016 08 17; 7:12499.
    View in: PubMed
    Score: 0.040
  100. Attenuation of G2-phase cell cycle checkpoint control is associated with increased frequencies of unrejoined chromosome breaks in human tumor cells. Radiat Res. 1996 Aug; 146(2):139-43.
    View in: PubMed
    Score: 0.040
  101. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene. 2017 02 02; 36(5):585-592.
    View in: PubMed
    Score: 0.040
  102. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.039
  103. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
    View in: PubMed
    Score: 0.039
  104. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
    View in: PubMed
    Score: 0.038
  105. Linking Cancer Metabolism to DNA Repair and Accelerated Senescence. Mol Cancer Res. 2016 Feb; 14(2):173-84.
    View in: PubMed
    Score: 0.038
  106. From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clin Cancer Res. 2016 Jan 01; 22(1):20-5.
    View in: PubMed
    Score: 0.038
  107. Radiation oncology and the new biology. Cancer J Sci Am. 1995 Sep-Oct; 1(3):174-9.
    View in: PubMed
    Score: 0.038
  108. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am. 1995 Sep-Oct; 1(3):204-9.
    View in: PubMed
    Score: 0.038
  109. Nanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May; 2(5):366-7.
    View in: PubMed
    Score: 0.037
  110. Growth factors alter the therapeutic ratio in radiotherapy. Cancer J Sci Am. 1995 May-Jun; 1(1):28-9.
    View in: PubMed
    Score: 0.037
  111. RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Res. 2015 Mar 31; 43(6):3180-96.
    View in: PubMed
    Score: 0.036
  112. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
    View in: PubMed
    Score: 0.036
  113. Cellular and molecular mechanisms of radioresistance. Cancer Treat Res. 1995; 74:131-40.
    View in: PubMed
    Score: 0.036
  114. Oligometastases. J Clin Oncol. 1995 Jan; 13(1):8-10.
    View in: PubMed
    Score: 0.036
  115. The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res. 2014 Jul 01; 74(13):3546-55.
    View in: PubMed
    Score: 0.034
  116. Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model. Theor Biol Med Model. 2014 Apr 12; 11:17.
    View in: PubMed
    Score: 0.034
  117. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.034
  118. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
    View in: PubMed
    Score: 0.032
  119. The role of cytokines in radiation oncology. Important Adv Oncol. 1993; 71-80.
    View in: PubMed
    Score: 0.031
  120. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.031
  121. Molecular targets to overcome radioresistance. Semin Oncol. 1992 Aug; 19(4 Suppl 11):14-20.
    View in: PubMed
    Score: 0.030
  122. Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys. 1992; 24(3):565-7.
    View in: PubMed
    Score: 0.029
  123. Chemotherapeutic and biologic radiation enhancement. Curr Opin Oncol. 1991 Dec; 3(6):1087-95.
    View in: PubMed
    Score: 0.029
  124. Where it's at really matters: in situ in vivo vascular endothelial growth factor spatially correlates with electron paramagnetic resonance pO2 images in tumors of living mice. Mol Imaging Biol. 2011 Dec; 13(6):1107-13.
    View in: PubMed
    Score: 0.029
  125. Possible applications of biotechnology to radiotherapy. Eur J Cancer. 1991; 27(4):405-7.
    View in: PubMed
    Score: 0.027
  126. Cellular and molecular aspects of human tumor radioresistance. Important Adv Oncol. 1991; 73-83.
    View in: PubMed
    Score: 0.027
  127. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.026
  128. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990 May; 8(5):911-34.
    View in: PubMed
    Score: 0.026
  129. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
    View in: PubMed
    Score: 0.025
  130. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
    View in: PubMed
    Score: 0.024
  131. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008 Sep 01; 98(3):202-6.
    View in: PubMed
    Score: 0.023
  132. Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol. 2007 Sep 10; 25(26):4090-5.
    View in: PubMed
    Score: 0.022
  133. Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis. 2007; 24(7):521-31.
    View in: PubMed
    Score: 0.021
  134. The maximum recovery potential of human tumor cells may predict clinical outcome in radiotherapy. Int J Radiat Oncol Biol Phys. 1987 May; 13(5):709-13.
    View in: PubMed
    Score: 0.021
  135. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
    View in: PubMed
    Score: 0.020
  136. Radioresistant and repair proficient cells may determine radiocurability in human tumors. Int J Radiat Oncol Biol Phys. 1986 Apr; 12(4):637-9.
    View in: PubMed
    Score: 0.020
  137. Bugging the intestinal response to radiation. Proc Natl Acad Sci U S A. 2005 Sep 20; 102(38):13363-4.
    View in: PubMed
    Score: 0.019
  138. Inherently radioresistant cells exist in some human tumors. Proc Natl Acad Sci U S A. 1985 Jul; 82(14):4732-5.
    View in: PubMed
    Score: 0.019
  139. Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol. 2005 Feb; 2(2):60-1.
    View in: PubMed
    Score: 0.018
  140. Quantitation of the response of human tumor spheroids to daily radiation exposures. Int J Radiat Oncol Biol Phys. 1984 Dec; 10(12):2323-7.
    View in: PubMed
    Score: 0.018
  141. STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition. Sci Adv. 2024 07 19; 10(29):eado0082.
    View in: PubMed
    Score: 0.017
  142. The role of DNA repair processes in the response of human tumors to fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1984 Jul; 10(7):1127-34.
    View in: PubMed
    Score: 0.017
  143. Repair of fractionated radiation in plateau phase cultures of human tumor cells and human multicellular tumor spheroids. Radiother Oncol. 1984 Jun; 2(1):41-7.
    View in: PubMed
    Score: 0.017
  144. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
    View in: PubMed
    Score: 0.017
  145. Repair of potentially lethal X ray damage and possible applications to clinical radiotherapy. Int J Radiat Oncol Biol Phys. 1983 Jan; 9(1):91-6.
    View in: PubMed
    Score: 0.016
  146. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
    View in: PubMed
    Score: 0.015
  147. Cellular repair factors influencing radiocurability of human malignant tumours. Br J Cancer. 1982 Jan; 45(1):10-6.
    View in: PubMed
    Score: 0.015
  148. Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther. 2001 Jun 10; 12(9):1109-31.
    View in: PubMed
    Score: 0.014
  149. X-ray sensitivity of human tumor cells in vitro. Int J Radiat Oncol Biol Phys. 1980 Apr; 6(4):437-40.
    View in: PubMed
    Score: 0.013
  150. The contribution of DNA ploidy to radiation sensitivity in human tumour cell lines. Br J Cancer. 1999 Feb; 79(5-6):744-7.
    View in: PubMed
    Score: 0.012
  151. Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomedicine. 2017 07; 13(5):1833-1839.
    View in: PubMed
    Score: 0.010
  152. Radiation oncology. JAMA. 1996 Jun 19; 275(23):1852-3.
    View in: PubMed
    Score: 0.010
  153. Potentially lethal damage repair as a possible determinant of human tumour radiosensitivity. Radiother Oncol. 1984 Jan; 1(3):263-9.
    View in: PubMed
    Score: 0.004
  154. Abnormal sensitivity of diploid skin fibroblasts from a family with gardner's syndrome to the lethal effects of X-irradiation, ultraviolet light and mitomycin-C. Mutat Res. 1980 Apr; 70(2):241-50.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.